An agency with the USA’s Department of Defence awarded Trius
Therapeutics Inc (CA) a grant to collaborate with Scripps Institution
of Oceanography at the University of California to develop novel
antibiotics directed against microorganisms that cause serious
infections. New anti-microbial compounds and mechanisms of action are
likely to have a commercial benefit as well in an age where bacterial
pathogens are acquiring resistance to existing antibiotics in both the
hospital and in the community.